Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2

Genitourinary Medicine

Volumn 73, Issue 1, 1997, Pages 5-11

  Heylen, Rachel ^a,b   Miller, Robert ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTACID AGENT; ASTEMIZOLE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; DAPSONE; DAUNORUBICIN; DOXORUBICIN; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; METHADONE; METRONIDAZOLE; PENTAMIDINE; PHENYTOIN; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SULFONAMIDE; TERFENADINE; THALIDOMIDE; TRIMETHOPRIM; UNINDEXED DRUG; VINBLASTINE; ZIDOVUDINE;

CRYSTALLURIA; DRUG INTERACTION; HEADACHE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT;

EID: 79960445716     PISSN: 02664348     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.73.1.5     Document Type: Review

References (32)

1. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic Hepatitis B infection. N Eng J Med 1995;333:1657-61.
2. EPIVER (Lamivudine, 3TC) Tablets. Summary of product characteristics Glaxo-Wellcome, August 1996.
3. Erron JJ, Benoit S, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4 + cells per cubic millimeter. N Eng J Med 1995;333:1662-9.
4. The CAESAR Trial (Protocol NUCB3007). Executive summary: preliminary results based on data up to 31 05 95.
5. Van Leeuwen R, Lange JMA, Hussey EK, et al. AIDS 1992;6:1471-5.
6. Angel JB, Hussey EK, Hall ST, Donn KH, Hall ST, Harker AJ, et al. Pharmacokinetics of 3TC (GR 109714X) administered with and without food to HIV infected patients. Drug Invest 1993;6:70-4.
7. Katlama C, Ingrand D, Loveday C, Clumech N, Malloley J, Straszewski S, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in anti retroviral-naive patients: a randomised controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25.
8. Strazewski S, Loveday C, Picazo JJ, Dellamonica P, Skinhoj P, Johnson MA, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomised controlled comparison with zidovudine monotherapy. JAMA 1996;276:111-7.
9. Condra JH, Schleif WA, Blahy OM, Gabreska LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71 (letter).
10. Collier A, Coombs RW, Schoenfield DA, Bassett RL, Timgone J, Baruch A, et al. AIDS Clinical Trials Group. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Eng J Med 1996;334:1011-7.
11. Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L, NV14256 Study Team. Saquinavir (Invirase SQV) vs Hivid (zalcitabine, ddC) vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take Retrovir (zidovudine, ZDV). Abstract MoB 410, 11th International Conference on AIDS, Vancouver, Canada, 7-12 July 1996.
12. Markowitz M, Saag M, Powderly WG, Murley AM, Hsu A, Valdec JM, et al. A preliminary study of ritonavir an inhibitor of HIV-1 protease to treat HIV-1 infection. N Eng J Med 1995;333:1543-9.
13. Danner SA, Carr A, Leonard JM, Lekman LM, Gudiol F, Gonzales J, et al. A short term study of the safety, pharmacokinetics and efficacy of ritonavir an inhibitor of HIV-1 protease. N Eng J Med 1995;333:1528-33.
14. Cameron B, Heath-Chiozi M, Kravciks S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with riton-avir: Update. MoB 411, 11th International Conference on AIDS, Vancouver, Canada, 7-12 July 1996.
15. Deutch P, Teppler H, Squires K. Antiviral activity of L-735,524 an HIV protease inhibitor in infected patients. Paper presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida 60-60, October 4-7 1994.
16. Carpenter CC, Fischl MA, Hammer SM, Hirsh MS, Jacobsen DM, Katzenstein DA, et al. Anti retroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
17. Invirase: summary of product characteristics. Roche. September 1996.
18. Moyle G. Saquinavir: a review of its development pharmacological properties and clinical use. Exp Opin Invest Drugs 1996;5:155-67.
19. Cameron W, Sun E, Markowitz M, Karavcik S, Mills R, Potthoff A, et al. Combination use of ritonavir and saquinavir in HIV infected patients: preliminary safety and activity data. Th B 934 11th International Conference on AIDS, Vancouver, Canada, 7-12 July 1996.
20. Crixivan: Summary of product characteristics. Merck Sharp and Dohme Ltd, October 1996.
21. The Indinavir (MK 639) Pharmacokinetic Study Group, Merck Laboratories Indinavir MK 639. Drug interaction studies. MoB 174, 11th International Conference on AIDS Vancouver, Canada, 7-12 July 1996.
22. Norvir: summary of product characteristics. Abbott Laboratories Ltd, August 1996.
23. Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Grannemann RG, Mawath CJ, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin associated adverse effects. MoB 171, 11th International Conference on AIDS, Vancouver, Canada, 7-12 July 1996.
24. Cato A, Cavanaugh JH, Shi H, Grannemann RG, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. MoB 1199, 11th International Conference on AIDS, Vancouver, Canada, 7-12 July 1996.
25. Personal Communication. Merck Sharp and Dohme 09 1096.
26. Personal Communication. Abbot Laboratories, September 1996.
27. Duong M, Sgro C, Grappin M, Birou F, Boibieux A. Renal failure after ritonavir. Lancet 1996;348:693-4.
28. Morse GD, Hu J, Ingalls E, Bartos L, D'Ambrosio R. In vitro studies of drug-drug protein binding displacement with delavirdine mesylate. XI International Conference on AIDS 1996, Vancouver, Canada: Abstract We.B. 3132.
29. Gilden D. Delavirdine/Protease Inhibitor interactions. Treatment Issues 1996;10:11-2.
30. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996;5:1183-99.
31. Personal Communication: Boehringer Ingleheim, 23 September 1996.
32. Personal Communication: Boehringer Ingleheim, 20 November 1996.